Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 13/20 | 0.46 |
| ▸ | SLC16A1 | P53985 | 12/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4125824 | 0.87 | SLC16A3 (0.38) | SLC16A3SLC16A1HTR2CSLC6A4 | |
| SCHEMBL3696583 | 0.87 | HTR2C (0.51) | SLC16A3SLC16A1HTR2CSLC6A4 | |
| SCHEMBL3701337 | 0.86 | SLC16A3 (0.36) | SLC16A3SLC16A1HTR2CSLC6A4HTT | |
| SCHEMBL3708988 | 0.85 | SLC16A3 (0.40) | SLC16A3SLC16A1HTR2CSLC6A4HTT | |
| SCHEMBL3697422 | 0.84 | SLC16A3 (0.40) | SLC16A3SLC16A1HTR2CSLC6A4 | |
| SCHEMBL4140873 | 0.83 | SLC16A3 (0.40) | SLC16A3SLC16A1RIPK1HTR2CSLC6A4 | |
| SCHEMBL4128944 | 0.82 | SLC16A3 (0.38) | SLC16A3SLC16A1HTR2CSLC6A4MEN1 | |
| SCHEMBL2838662 | 0.82 | SLC16A3 (0.38) | SLC16A3SLC16A1HTR2CSLC6A4MEN1 | |
| SCHEMBL4132125 | 0.81 | SLC16A3 (0.40) | SLC16A3SLC16A1HTR2CSLC6A4ALDH1A1 | |
| SCHEMBL4134984 | 0.80 | SLC16A3 (0.36) | SLC16A3SLC16A1HTR2CSLC6A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| WO-2009041705-A9 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2009-08-13 | — | — | WO | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | SLC16A3 2809/4885SLC16A1 2925/4885RIPK1 4203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.